Infection Prevention and Control, Gwinnett Medical Center, Lawrenceville, GA.
Infection Prevention and Control, Gwinnett Medical Center, Lawrenceville, GA.
Am J Infect Control. 2020 Mar;48(3):333-336. doi: 10.1016/j.ajic.2019.08.012. Epub 2019 Sep 10.
The impact of discontinuing contact precautions (CPs) for patients with select multidrug-resistant organisms on bacteremia infection rates was evaluated in this quality improvement project.
The removal of use of CPs, with increased focus on standard precautions, for all patients with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE) colonization/infection was piloted via a quality improvement project over a 3-month period.
CP was discontinued in December 2018. Comparing 3 months pre- and postchange, the overall incidence density rate decreased for hospital-onset (HO) laboratory-identified (LabID) MRSA bacteremia (0.07 vs 0.02; P = .52), whereas HO LabID VRE bacteremia rates remained the same (0.00 vs 0.00). Overall estimated financial savings, including personal protective equipment ($15,375) and staff time ($17,165), was $32,540 for the project period, with annualized estimated savings of $130,160.
In this pilot study evaluating the discontinuance of CPs, there was no evidence of an increase in HO MRSA or VRE LabID bacteremia incidence density rates. This practice change may be safely implemented at similar health care facilities.
本质量改进项目评估了停止对某些多重耐药菌患者实施接触预防措施(CPs)对菌血症感染率的影响。
通过质量改进项目,对所有耐甲氧西林金黄色葡萄球菌(MRSA)或万古霉素耐药肠球菌(VRE)定植/感染患者停用 CPs,并更加注重标准预防措施,为期 3 个月。
CP 于 2018 年 12 月停止使用。与改变前的 3 个月相比,医院获得性(HO)实验室鉴定(LabID)MRSA 菌血症的总发生率密度降低(0.07 比 0.02;P=0.52),而 HO LabID VRE 菌血症率保持不变(0.00 比 0.00)。项目期间的总估计节省费用包括个人防护设备(15375 美元)和员工时间(17165 美元)为 32540 美元,年化估计节省 130160 美元。
在这项评估停止使用 CPs 的试点研究中,HO MRSA 或 VRE LabID 菌血症发生率密度没有增加的证据。这种做法的改变可以在类似的医疗机构中安全实施。